

Biosignal Limited
Suite 145, Level 1
National Innovation Centre
Australian Technology Park
EVELEIGH NSW 1430

Telephone +61 2 9209 4126
Facsimile +61 2 9209 4306

ACN 071 781 383
ABN 46 071 781 383

ASX Announcement

ACQUISITION FINANCING

21 September 2009, Melbourne: The Board of Biosignal (ASX:BOS) is pleased to advise the market that it has raised \$900,000 by way of a convertible note from professional and sophisticated investors to part finance the completion of the previously announced RGM Acquisition and to meet the general working capital requirements of the company.

Two hundred and twenty thousand dollars (\$220,000) has been advanced to BOS on entering into the note deed, with the balance of the funds available to BOS, subject to shareholder approval to the terms of the note in a further tranche of six hundred and eighty thousand dollars (\$680,000). The note carries a 10% coupon, a 12 month term and is convertible into BOS ordinary shares on completion of the planned RGM Acquisition. As security, the note holders will be granted a charge over the assets of BOS until the note is repaid or converted into BOS ordinary shares.

Enquiries: Biosignal Ltd
Mr. Tim Boyd
Tel. +61 (0)406 993 054

About Biosignal

Biosignal is commercialising a distinctive anti-bacterial technology. This technology is effective across applications ranging from industrial to medical products.

For more information see the Biosignal website at www.biosignal.com.au